7 terminated, 4 completed, 3 withdrawn. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Terminated 6, Completed 4, Withdrawn 3 |
| Phase 2 | 3 | Terminated 3 |
Follow TAK-659: new trials by email Literature Review of TAK-659 trials Research Report on TAK-659
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib TAK-659, Ixazomib - AML, AML, Adult | Phase 1 / Phase 2 | Terminated | H Scott Boswell | 8 | 2019-09-20 | 2023-09-13 |
| A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) TAK-659, NKTR-214 - Lymphoma, Non-Hodgkin | Phase 1 | Withdrawn | Calithera Biosciences, Inc | 2019-04-03 | 2023-02-08 | |
| Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 1 | Completed | Northwestern University | 12 | 2019-03-13 | 2025-06-18 |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Mivavotinib, Paclitaxel, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Ovarian Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 52 | 2019-03-05 | 2023-02-28 |
| A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies [14C]-TAK-659, TAK-659 - Advanced Solid Neoplasms, Lymphoma Neoplasms | Phase 1 | Withdrawn | Calithera Biosciences, Inc | 2018-05-10 | 2023-02-08 | |
| A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor TAK-659 - Lymphoma, Malignant, Advanced Solid Neoplasms | Phase 1 | Withdrawn | Calithera Biosciences, Inc | 2018-02-28 | 2023-02-08 | |
| A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma TAK-659, Venetoclax - Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse | Phase 1 | Completed | Calithera Biosciences, Inc | 43 | 2018-02-16 | 2023-02-08 |
| TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) TAK-659 - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Calithera Biosciences, Inc | 49 | 2017-10-10 | 2023-02-08 |
| A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) TAK-659 - Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Marginal Zone | Phase 1 | Terminated | Calithera Biosciences, Inc | 17 | 2017-08-01 | 2023-02-08 |
| A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma TAK-659, Bendamustine, Rituximab - Lymphoma, Non-Hodgkin | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 43 | 2017-03-05 | 2022-02-18 |
| A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors TAK-659, Nivolumab - Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Calithera Biosciences, Inc | 41 | 2016-08-12 | 2023-02-08 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma MLN1117, TAK-659, Alisertib - Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 32 | 2015-10-15 | 2019-09-20 |
| Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) TAK-659 - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 43 | 2015-03-09 | 2023-02-08 |
| A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies TAK-659 - Advanced Solid Tumor and Lymphoma Malignancies | Phase 1 | Completed | Calithera Biosciences, Inc | 143 | 2013-12-31 | 2023-02-08 |
Lymphoma, Non-Hodgkin (4) · Lymphoma, Large B-Cell, Diffuse (3) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Lymphoma, Follicular (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Calithera Biosciences, Inc (9) · Millennium Pharmaceuticals, Inc. (2) · H Scott Boswell (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1)
United States (12) · Canada (5) · Spain (4) · Italy (3) · United Kingdom (3) · France (1) · Germany (1) · Japan (1) · South Korea (1)
H Scott Boswell, MD (1) · Reem Karmali (1) · Siqing Fu (1)
PMID 32327472, PMID 36226495, PMID 36702329, PMID 38501219, PMID 41748936
2016 (3), 2017 (2), 2015 (1), P30CA016672 (1), P30CA060553 (1)